Treatment response and outcomes in the EXT1-positive and EXT1-negative cases in confirmed and suspected LMN
| Confirmed LMN | Suspected LMN | |||
| EXT1 positive (n=22) | EXT1 negative (n=8) | EXT1 positive (n=6) | EXT1 negative (n=31) | |
| Immunosuppression, n (%) | 21 (95.5) | 5 (62.5) | 5 (83.3) | 12 (38.7) |
| Non-immunosuppression, n (%) | 1 (4.5) | 0 (0.0) | 1 (16.7) | 14 (45.2) |
| Dialysis, n (%) | 0 (0.0)* | 3 (37.5) | 0 (0.0) | 1 (3.2) |
| Follow-up time, month | 48 (24–120) | 97.5 (17.3–174) | 12 (10–15) | 24 (8–60) |
| Complete remission, n (%) | 17 (77.3)* | 4 (50.0) | 3 (50.0)* | 3 (9.6) |
| Partial remission, n (%) | 3 (13.6) | 2 (25.0) | 2 (33.3) | 9 (29.0) |
| No remission, n (%) | 2 (9.1) | 2 (25.0) | 1 (16.6)* | 19 (61.3) |
| ESKD, n (%) | 0 (0.0)* | 3 (37.5) | 0 (0.0) | 1 (3.2) |
Data were presented as n (%) or medians (IQR). Data with significant differences are highlighted in bold.
Immunosuppression: prednisone+cyclophosphamide/mycophenolate mofetil/hydroxychloroquine; non-immunosuppression: ACE inhibitors+angiotensin receptor blocker or traditional Chinese medicine.
*EXT1-positive cases compared with EXT1-negative cases; p<0.05.
ESKD, end-stage kidney disease; EXT1, exostosin 1; LMN, lupus membranous nephropathy.